Clinical trial · no report yet · Phase 3
PSMAddition
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- NCT04720157 ↗
- Active not recruiting
- Novartis Pharmaceuticals
- 299 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 139 | |
| YouTube | 85 | |
| Podcasts | 68 | |
| X videos | 7 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- 177Lu-PSMA-617; 68Ga-PSMA-11; ARDT; ADT
- Arms
- 177Lu-PSMA-617 · Experimental
- Standard of Care · Active comparator
- Enrollment
- 1,140
- Primary outcomes
- Radiographic Progression Free Survival (rPFS)
- Sponsor
- Novartis Pharmaceuticals with Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
- Start
- Jun 9, 2021
- Primary completion
- Jan 13, 2025
- Results posted
- No
- Registry record
- NCT04720157 · updated Jun 8, 2026
Publications
linked from the registry- Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, Barthelemy P, Dai D, Lee JL, Nordquist L, Szmulewitz RZ, Wiechno P, Yovine A, Smith L, Bouillaud E, Sakharova O, Morris MJ; PSMAddition Investigators. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 6:S0140-6736(26)01092-5. doi: 10.1016/S0140-6736(26)01092-5. Online ahead of print. PubMed 42561994